Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.
NCT ID: NCT04322279
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
81 participants
OBSERVATIONAL
2020-03-09
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital.
Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action.
Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.
In this study, we aim to evaluate the virological and clinical outcomes of subjects following a contact at high/moderate risk of SARS-CoV-2 acquisition, in community-subjects and/or healthcare workers.
The study population is represented by all subjects who had a contact with laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at high/moderate risk of SARS-CoV-2 acquisition.
This include both children and adult subjects, subject without social security, and healthcare workers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns
NCT04355234
Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection
NCT04624997
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
NCT04664023
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
NCT04448145
Serological Study of the Exposure of Personnel to COVID-19
NCT04422977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood sampling for determination of the presence of SARS-CoV-2 type M immunoglobulins or type G immunoglobulins.
Blood sampling for whole exome sequencing
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serology
SARS-CoV-2 serology
Sequencing
Whole exome sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2 case;
* Obtaining informed consent.
Exclusion Criteria
* Subject deprived of freedom
* Subject under a legal protective measure
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier DUVAL, MD
Role: PRINCIPAL_INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau
Tours, , France
Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon
Besançon, , France
Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin
Bordeaux, , France
Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand
Clermont-Ferrand, , France
Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne
Dijon, , France
Centre d'investigation clinique 1406 CHU Grenoble
Grenoble, , France
Centre d'Investigation Clinique 1403 -CHU Lille
Lille, , France
Centre d'Investigation Clinique Hôpital Saint Louis
Paris, , France
Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard
Paris, , France
Hôpital Cochin CIC 1417 Bâtiment Lavoisier
Paris, , France
Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou
Rennes, , France
Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord
Saint-Denis, , France
Département maladie infectieux CHU Saint Etienne
Saint-Etienne, , France
Centre d'Investigation Clinique Ile de la Réunion CHU sud
Saint-Pierre, , France
Centre Investigation Clinique 1433 CHRU de NANCY
Vandœuvre-lès-Nancy, , France
Service de Maladies infectieuses et tropicales Centre hospitalier
Cayenne, , French Guiana
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00609-30
Identifier Type: REGISTRY
Identifier Source: secondary_id
C20-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.